Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544567 · ClinicalTrials.gov registry record · Phase 2
A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 study of Angiosarcoma of Skin, sponsored by Athenex.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 10
- Study locations
NCT03544567: Completed Phase 2 study of Angiosarcoma of Skin, sponsored by Athenex.
NCT03544567 is a Phase 2 study of Angiosarcoma of Skin that has completed, run by Athenex. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03544567, a Phase 2 study of Angiosarcoma of Skin, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
Primary Outcome
To determine the response rate 6 months after initiation of treatment with Oraxol in subjects with cutaneous angiosarcoma
Conditions Studied
Interventions
- DRUG Oraxol
Study Locations (10)
Other
- Prince of Wales Hospital, Shatin - Hong Kong
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hosptial - Taipei
- University College London Hospitals NHS Foundation Trust - London
- The Royal Marsden NHS Foundation Trust - London
- The Christie NHS Foundation Trust, Manchester - Manchester
Texas
- Texas Oncology - Dallas
- MD Anderson Cancer Center - Houston
New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- University of Washington/Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 2 |
What the finished NCT03544567 record still lists
NCT03544567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Angiosarcoma of Skin appearing as the primary indexed condition, and to 1 intervention - of which Oraxol is the first listed.
NCT03544567 lists 10 locations in 4 states (Other, Texas, New York).
Frequently Asked Questions
What is clinical trial NCT03544567 about?
NCT03544567 is a clinical study titled "A Study of Oraxol in Subjects With Cutaneous Angiosarcoma". This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
What is the current status of trial NCT03544567?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2018-12-21. Estimated completion is 2023-05-12.
What conditions does trial NCT03544567 study?
This clinical trial studies the following conditions: Angiosarcoma of Skin.
What interventions are being tested in trial NCT03544567?
The interventions under investigation include: Oraxol (DRUG).
Who is sponsoring clinical trial NCT03544567?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03544567 being conducted?
This trial has 10 study locations across New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03544567's enrollment target sits among peer trials
48 1265th of 2000 higher than 718 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI